navitoclax,pelabresib,ruxolitinib
abbvie,Constellation Pharmaceuticals,novartis,incyte
['mpnsm', '#mpn', 'navitoclax', 'paradigm']
exciting data on frontline rux combos in mf presented today at #eha22! rux+navitoclax data new: 63% svr35, 41% tss50, 27% bmf improvement at w24 (68%, 56% and 28% for rux+pelabresib). very interesting vaf and cytokine reduction data with rux/pelabresib. paradigm shift? #mpnsm
Associate Professor, Leukemia at MD Anderson; myeloproliferative neoplasm expert, NCCN panelist. Tweets reflect my own views; not necessarily my institution's.